28 Apr 2026
As part of Singapore's National Precision Medicine program (PRECISE), the Pre-emptive Pharmacogenomics Clinical Implementation Pilot (PPGx-CIP) tests the feasibility of integrating PPGx testing into local healthcare system. Reactive testing often leads to delay of days or weeks before a prescription can be adjusted, whereas pre-emptive testing ensures that a patient's genetic profile is already in the electronic medical record (EMR), allowing for real-time clinical decision support at the point of prescribing. The pilot, involving over 2,000 patients across eight institutions, demonstrated that integrating PGx into routine clinical workflows is feasible, underlying the promise of impacting patient safety through preventing adverse drug reactions.
The webinar was led and moderated by Dr Elaine Lo, Principal Clinical Pharmacist, National University Hospital and brought together thirteen members from various specialties. It provided a platform for some fruitful discussion on key areas such as:
-
the high prevalence of actionable genetic variants;
-
the pre-emptive implementation model;
-
critical drug-gene examples in the Singapore context;
-
clinical interpretation caveats; and
-
the future outlook and scaling up precision medicine.
